Nanotechnological carriers for cancer chemotherapy: the state of the art.
暂无分享,去创建一个
Jaime Conceição | Maria Helena Amaral | Marilene Estanqueiro | J. S. Sousa Lobo | José Manuel Sousa Lobo | M. Estanqueiro | J. Conceição | M. H. Amaral | Marilene Estanqueiro | Jaime Conceição
[1] Andreas Wagner,et al. Liposomes produced in a pilot scale: production, purification and efficiency aspects. , 2002, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[2] Shuming Nie,et al. Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery , 2006, Molecular Cancer Therapeutics.
[3] Yi Yan Yang,et al. Co-delivery of thioridazine and doxorubicin using polymeric micelles for targeting both cancer cells and cancer stem cells. , 2014, Biomaterials.
[4] Rahul P Gangwal,et al. Oral delivery of anticancer drugs: challenges and opportunities. , 2013, Journal of controlled release : official journal of the Controlled Release Society.
[5] James R. Dewald,et al. A New Class of Polymers: Starburst-Dendritic Macromolecules , 1985 .
[6] A. Gabizon. Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of Chemotherapy , 2001, Cancer investigation.
[7] Ick Chan Kwon,et al. Super pH-sensitive multifunctional polymeric micelle for tumor pH(e) specific TAT exposure and multidrug resistance. , 2008, Journal of controlled release : official journal of the Controlled Release Society.
[8] Robert Gurny,et al. Poly(lactic acid) nanoparticles labeled with biologically active Neutravidin for active targeting. , 2004, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[9] Ahmed O Elzoghby,et al. Albumin-based nanoparticles as potential controlled release drug delivery systems. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[10] Sudesh Kumar Yadav,et al. Biodegradable polymeric nanoparticles based drug delivery systems. , 2010, Colloids and surfaces. B, Biointerfaces.
[11] D. Fischer,et al. Surface-modified biodegradable albumin nano- and microspheres. II: effect of surface charges on in vitro phagocytosis and biodistribution in rats. , 1998, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[12] John W. Park,et al. Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development. , 2008, Journal of pharmaceutical sciences.
[13] V. Torchilin,et al. Structure and design of polymeric surfactant-based drug delivery systems. , 2001, Journal of controlled release : official journal of the Controlled Release Society.
[14] T. Welte,et al. Nanoparticle-based diagnosis and therapy. , 2006, Current drug targets.
[15] Catarina Pinto Reis,et al. Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. , 2006, Nanomedicine : nanotechnology, biology, and medicine.
[16] Vladimir P Torchilin,et al. PEG-based micelles as carriers of contrast agents for different imaging modalities. , 2002, Advanced drug delivery reviews.
[17] John W. Park. Liposome-based drug delivery in breast cancer treatment , 2002, Breast Cancer Research.
[18] V. Torchilin,et al. Immunoliposomes and PEGylated immunoliposomes: possible use for targeted delivery of imaging agents. , 1994, ImmunoMethods.
[19] A. Ray,et al. Poly(amido amine) dendrimers as absorption enhancers for oral delivery of camptothecin. , 2013, International journal of pharmaceutics.
[20] R. Müller,et al. Investigation on the viscoelastic properties of lipid based colloidal drug carriers. , 2000, International journal of pharmaceutics.
[21] Jiwon Kim,et al. 5-fluorouracil induced cardiotoxicity: review of the literature. , 2012, Cardiology journal.
[22] P. Cullis,et al. Liposomal drug delivery systems: from concept to clinical applications. , 2013, Advanced drug delivery reviews.
[23] D Needham,et al. Increased microvascular permeability contributes to preferential accumulation of Stealth liposomes in tumor tissue. , 1993, Cancer research.
[24] K. K. Singh,et al. Etoposide loaded solid lipid nanoparticles for curtailing B16F10 melanoma colonization in lung. , 2014, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[25] K. Gelmon,et al. Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] A. Schätzlein,et al. Ultradeformable lipid vesicles can penetrate the skin and other semi-permeable barriers unfragmented. Evidence from double label CLSM experiments and direct size measurements. , 2002, Biochimica et biophysica acta.
[27] D. Kerr,et al. Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] Shengfu Chen,et al. Highly hemocompatible zwitterionic micelles stabilized by reversible cross-linkage for anti-cancer drug delivery. , 2014, Colloids and surfaces. B, Biointerfaces.
[29] J. Iqbal,et al. Development and in vivo evaluation of an oral drug delivery system for paclitaxel. , 2011, Biomaterials.
[30] R. Wiwattanapatapee,et al. Carboxymethylcellulose-tetrahydrocurcumin conjugates for colon-specific delivery of a novel anti-cancer agent, 4-amino tetrahydrocurcumin. , 2014, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[31] P. Trail,et al. Antitumor activity of carcinoma-reactive BR96-doxorubicin conjugate against human carcinomas in athymic mice and rats and syngeneic rat carcinomas in immunocompetent rats. , 1997, Cancer research.
[32] Jim Jiao. Polyoxyethylated nonionic surfactants and their applications in topical ocular drug delivery. , 2008, Advanced drug delivery reviews.
[33] A. Po,et al. Oral vaccines: Design and delivery , 1991 .
[34] R. Müller,et al. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. , 2004, International journal of pharmaceutics.
[35] Hua Ai,et al. Micellar carriers based on block copolymers of poly(ε-caprolactone) and poly(ethylene glycol) for doxorubicin delivery , 2004 .
[36] S. Mitragotri,et al. Endocytosis and Intracellular Distribution of PLGA Particles in Endothelial Cells: Effect of Particle Geometry. , 2010, Macromolecular rapid communications.
[37] Xiguang Chen,et al. Construction of hyaluronic acid noisome as functional transdermal nanocarrier for tumor therapy. , 2013, Carbohydrate polymers.
[38] Jinming Gao,et al. Theranostic nanomedicine for cancer. , 2008, Nanomedicine.
[39] S M Moghimi,et al. Long-circulating and target-specific nanoparticles: theory to practice. , 2001, Pharmacological reviews.
[40] L. Brown. Commercial challenges of protein drug delivery , 2005, Expert opinion on drug delivery.
[41] E. Peira,et al. Deformable liposomes for dermal administration of methotrexate. , 2004, International journal of pharmaceutics.
[42] P. Kesharwani,et al. Dendrimer toxicity: Let's meet the challenge. , 2010, International journal of pharmaceutics.
[43] R. Nitschke,et al. Quantum dots versus organic dyes as fluorescent labels , 2008, Nature Methods.
[44] K. Ulbrich,et al. Polymer conjugates of doxorubicin bound through an amide and hydrazone bond: Impact of the carrier structure onto synergistic action in the treatment of solid tumours. , 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[45] Felix Kratz,et al. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. , 2008, Journal of controlled release : official journal of the Controlled Release Society.
[46] D. Discher,et al. Shape effects of filaments versus spherical particles in flow and drug delivery. , 2007, Nature nanotechnology.
[47] Antje J Baeumner,et al. Liposomes in analyses. , 2006, Talanta.
[48] Jun Fang,et al. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. , 2011, Advanced drug delivery reviews.
[49] S. Eksborg,et al. D-Methionine and cisplatin ototoxicity in the guinea pig: D-methionine influences cisplatin pharmacokinetics , 2002, Hearing Research.
[50] Yong Hu,et al. Study on docetaxel-loaded nanoparticles with high antitumor efficacy against malignant melanoma. , 2009, Acta biochimica et biophysica Sinica.
[51] P. Trail,et al. Site‐directed delivery of anthracyclines for treatment of cancer , 1995 .
[52] E. Eisenhauer,et al. Current perspectives on camptothecins in cancer treatment. , 1996, British Journal of Cancer.
[53] A. Estella-Hermoso de Mendoza,et al. Efficacy of edelfosine lipid nanoparticles in breast cancer cells. , 2013, International journal of pharmaceutics.
[54] V. Torchilin,et al. Targeted accumulation of polyethylene glycol‐coated immunoliposomes in infarcted rabbit myocardium , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[55] T. Minko,et al. Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA. , 2013, Journal of controlled release : official journal of the Controlled Release Society.
[56] Hong Yuan,et al. Drug resistance reversal activity of anticancer drug loaded solid lipid nanoparticles in multi-drug resistant cancer cells. , 2013, Colloids and surfaces. B, Biointerfaces.
[57] K. Ulbrich,et al. Cytostatic and immunomobilizing activities of polymer-bound drugs: experimental and first clinical data. , 2003, Journal of controlled release : official journal of the Controlled Release Society.
[58] S. Simões,et al. Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. , 2002, Journal of controlled release : official journal of the Controlled Release Society.
[59] Yun-Xia Li,et al. Hyaluronic acid-coated nanostructured lipid carriers for targeting paclitaxel to cancer. , 2013, Cancer letters.
[60] S. Chaudhari,et al. Niosomes: novel sustained release nonionic stable vesicular systems--an overview. , 2012, Advances in colloid and interface science.
[61] Y. Maitani,et al. Entrapment of bleomycin in ultra-deformable liposomes , 2003 .
[62] T. Allen,et al. Liposomes , 2012, Drugs.
[63] R. Duncan,et al. Dendrimer biocompatibility and toxicity. , 2005, Advanced drug delivery reviews.
[64] R K Jain,et al. Barriers to drug delivery in solid tumors. , 1994, Scientific American.
[65] P. Trail,et al. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. , 1993, Science.
[66] R. Müller,et al. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. , 2002, Advanced drug delivery reviews.
[67] Shonagh Walker,et al. The status of platinum anticancer drugs in the clinic and in clinical trials. , 2010, Dalton transactions.
[68] Yuliang Zhao,et al. TPGS-stabilized NaYbF4:Er upconversion nanoparticles for dual-modal fluorescent/CT imaging and anticancer drug delivery to overcome multi-drug resistance. , 2015, Biomaterials.
[69] B. W. Barry. Is transdermal drug delivery research still important today? , 2001, Drug discovery today.
[70] A. Lowman,et al. Biodegradable nanoparticles for drug delivery and targeting , 2002 .
[71] Lin Zhu,et al. Targeted delivery of methotrexate to skeletal muscular tissue by thermosensitive magnetoliposomes. , 2009, International journal of pharmaceutics.
[72] V. Roy,et al. Safety and Efficacy of nab-Paclitaxel in the Treatment of Patients with Breast Cancer , 2011, Breast cancer : basic and clinical research.
[73] D. Bissett,et al. Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT) , 2004, British Journal of Cancer.
[74] R. Müller,et al. Solid lipid nanoparticles (SLN) for controlled drug delivery , 1996 .
[75] V. Torchilin,et al. Poly(ethylene glycol)-coated anti-cardiac myosin immunoliposomes: factors influencing targeted accumulation in the infarcted myocardium. , 1996, Biochimica et biophysica acta.
[76] R. Müller,et al. Cetyl palmitate-based NLC for topical delivery of Coenzyme Q(10) - development, physicochemical characterization and in vitro release studies. , 2007, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[77] J. Fréchet,et al. Stimuli-responsive supramolecular assemblies of linear-dendritic copolymers. , 2004, Journal of the American Chemical Society.
[78] Ze Lu,et al. Paclitaxel-Loaded Gelatin Nanoparticles for Intravesical Bladder Cancer Therapy , 2004, Clinical Cancer Research.
[79] C. Pouton,et al. Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[80] G. V. Patil,et al. Biopolymer albumin for diagnosis and in drug delivery , 2003 .
[81] Forrest M Kievit,et al. Cancer Nanotheranostics: Improving Imaging and Therapy by Targeted Delivery Across Biological Barriers , 2011, Advanced materials.
[82] Y. Shimada,et al. Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[83] H. von Briesen,et al. Human serum albumin-polyethylenimine nanoparticles for gene delivery. , 2003, Journal of controlled release : official journal of the Controlled Release Society.
[84] Maruyama,et al. Possibility of active targeting to tumor tissues with liposomes. , 1999, Advanced drug delivery reviews.
[85] F. Muggia,et al. Liposomal encapsulated anthracyclines: new therapeutic horizons , 2001, Current oncology reports.
[86] T. Xu,et al. Design, synthesis and potent pharmaceutical applications of glycodendrimers: a mini review. , 2007, Current drug discovery technologies.
[87] J. Schwarzbauer,et al. Albumin-derived nanocarriers: substrates for enhanced cell adhesive ligand display and cell motility. , 2006, Biomaterials.
[88] Samir Mitragotri,et al. Red blood cell-mimicking synthetic biomaterial particles , 2009, Proceedings of the National Academy of Sciences.
[89] P. Nayak,et al. Preparation and characterization of chitosan–polylactide composites blended with Cloisite 30B for control release of the anticancer drug paclitaxel , 2011 .
[90] Hao Peng,et al. The formulation and delivery of curcumin with solid lipid nanoparticles for the treatment of on non-small cell lung cancer both in vitro and in vivo. , 2013, Materials science & engineering. C, Materials for biological applications.
[91] M. Dewhirst,et al. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. , 2000, Cancer research.
[92] Kazunori Kataoka,et al. Progress of drug-loaded polymeric micelles into clinical studies. , 2014, Journal of controlled release : official journal of the Controlled Release Society.
[93] Antony D'Emanuele,et al. Dendrimer-drug interactions. , 2005, Advanced drug delivery reviews.
[94] D. Herrmann. Changes in cellular lipid synthesis of normal and neoplastic cells during cytolysis induced by alkyl lysophospholipid analogues. , 1985, Journal of the National Cancer Institute.
[95] J. Kopeček,et al. HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line. , 1998, Journal of controlled release : official journal of the Controlled Release Society.
[96] T. Minko. Drug targeting to the colon with lectins and neoglycoconjugates. , 2004, Advanced drug delivery reviews.
[97] Y. Obata,et al. Novel ultra-deformable vesicles entrapped with bleomycin and enhanced to penetrate rat skin. , 2006, Journal of controlled release : official journal of the Controlled Release Society.
[98] I. Zuhorn,et al. Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. , 2004, The Biochemical journal.
[99] E K Rowinsky,et al. The current status of camptothecin analogues as antitumor agents. , 1993, Journal of the National Cancer Institute.
[100] Yoshiyuki Hattori,et al. Ultra-deformable liposomes containing bleomycin: in vitro stability and toxicity on human cutaneous keratinocyte cell lines. , 2005, International journal of pharmaceutics.
[101] D. Needham. Materials Engineering of Lipid Bilayers for Drug Carrier Performance , 1999 .
[102] Tongwen Xu,et al. Design of biocompatible dendrimers for cancer diagnosis and therapy: current status and future perspectives. , 2011, Chemical Society reviews.
[103] R. Fram,et al. XMT-1001, a novel polymeric camptothecin pro-drug in clinical development for patients with advanced cancer. , 2009, Advanced drug delivery reviews.
[104] Susan O'Brien,et al. Phase I/II trial of nanomolecular liposomal annamycin in adult patients with relapsed/refractory acute lymphoblastic leukemia. , 2013, Clinical lymphoma, myeloma & leukemia.
[105] M. Dewhirst,et al. The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors. , 2001, Advanced drug delivery reviews.
[106] D. Paolino,et al. Paclitaxel-loaded ethosomes®: potential treatment of squamous cell carcinoma, a malignant transformation of actinic keratoses. , 2012, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[107] J. Wanders,et al. Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[108] Samir Mitragotri,et al. Factors that control the circulation time of nanoparticles in blood: challenges, solutions and future prospects. , 2010, Current pharmaceutical design.
[109] Gustavo Helguera,et al. The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. , 2006, Clinical immunology.
[110] Y. Sakka,et al. Single-phased luminescent mesoporous nanoparticles for simultaneous cell imaging and anticancer drug delivery. , 2011, Biomaterials.
[111] Umesh Gupta,et al. Dendrimers: novel polymeric nanoarchitectures for solubility enhancement. , 2006, Biomacromolecules.
[112] V. Torchilin,et al. Immunoconjugates and long circulating systems: origins, current state of the art and future directions. , 2013, Advanced drug delivery reviews.
[113] W. McGuire,et al. Breast Cancer 4 , 1981, Springer US.
[114] A. Huang,et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. , 1998, The New England journal of medicine.
[115] K. Kono,et al. Synthesis of polyamidoamine dendrimers having poly(ethylene glycol) grafts and their ability to encapsulate anticancer drugs. , 2000, Bioconjugate chemistry.
[116] F. Nicoletta,et al. Doxorubicin loaded magneto-niosomes for targeted drug delivery. , 2013, Colloids and surfaces. B, Biointerfaces.
[117] D. Kerr,et al. Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. , 2009, International journal of oncology.
[118] Jayanth Panyam,et al. Rapid endo‐lysosomal escape of poly(DL‐lactide‐coglycolide) nanoparticles: implications for drug and gene delivery , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[119] S. Zerp,et al. Alkyl-lysophospholipids as anticancer agents and enhancers of radiation-induced apoptosis. , 2001, International journal of radiation oncology, biology, physics.
[120] J. Varshosaz,et al. Synthesis of Pluronic® F127-poly (methyl vinyl ether-alt-maleic acid) copolymer and production of its micelles for doxorubicin delivery in breast cancer , 2014 .
[121] C. Rhodes,et al. Preparation and characterization of liposomes as therapeutic delivery systems: a review. , 1995, Pharmaceutica acta Helvetiae.
[122] Mauro Ferrari,et al. Intravascular Delivery of Particulate Systems: Does Geometry Really Matter? , 2008, Pharmaceutical Research.
[123] Xuesi Chen,et al. Well-defined polymer-drug conjugate engineered with redox and pH-sensitive release mechanism for efficient delivery of paclitaxel. , 2014, Journal of controlled release : official journal of the Controlled Release Society.
[124] J. Schellens,et al. Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel , 2001, Anti-cancer drugs.
[125] M. Khil,et al. Preparation, characterization, in-vitro drug release and cellular uptake of poly(caprolactone) grafted dextran copolymeric nanoparticles loaded with anticancer drug. , 2009, Journal of biomedical materials research. Part A.
[126] R. Müller,et al. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. , 2000, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[127] M. Ferrari. Cancer nanotechnology: opportunities and challenges , 2005, Nature Reviews Cancer.
[128] P. Štěpánek,et al. Physicochemical aspects behind the size of biodegradable polymeric nanoparticles: A step forward , 2013 .
[129] Vladimir P. Torchilin,et al. Immunomicelles: Targeted pharmaceutical carriers for poorly soluble drugs , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[130] L. Murray,et al. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[131] R. Strickley. Solubilizing Excipients in Oral and Injectable Formulations , 2004, Pharmaceutical Research.
[132] Yoav D Livney,et al. β-Casein nanoparticle-based oral drug delivery system for potential treatment of gastric carcinoma: stability, target-activated release and cytotoxicity. , 2012, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[133] Jinwoo Cheon,et al. Chemical design of nanoparticle probes for high-performance magnetic resonance imaging. , 2008, Angewandte Chemie.
[134] T. Xu,et al. Dendrimers as drug carriers: applications in different routes of drug administration. , 2008, Journal of pharmaceutical sciences.
[135] S. Nie,et al. Therapeutic Nanoparticles for Drug Delivery in Cancer Types of Nanoparticles Used as Drug Delivery Systems , 2022 .
[136] A. Aderem,et al. Mechanisms of phagocytosis in macrophages. , 1999, Annual review of immunology.
[137] Abraham H. Abouzeid,et al. Polyethylene glycol-phosphatidylethanolamine (PEG-PE)/vitamin E micelles for co-delivery of paclitaxel and curcumin to overcome multi-drug resistance in ovarian cancer. , 2014, International journal of pharmaceutics.
[138] S. Jain,et al. A PEGylated dendritic nanoparticulate carrier of fluorouracil. , 2003, International journal of pharmaceutics.
[139] Xing Guo,et al. Redox-responsive polyanhydride micelles for cancer therapy. , 2014, Biomaterials.
[140] K. Nugent,et al. Cisplatin Nephrotoxicity: A Review , 2007, The American journal of the medical sciences.
[141] Fabian Kiessling,et al. Nanotheranostics and image-guided drug delivery: current concepts and future directions. , 2010, Molecular pharmaceutics.
[142] Michael Hawkins,et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[143] O. Boerman,et al. Liposomes for scintigraphic detection of infection and inflammation. , 1999, Advanced drug delivery reviews.
[144] Clemens Burda,et al. The unique role of nanoparticles in nanomedicine: imaging, drug delivery and therapy. , 2012, Chemical Society reviews.
[145] E. Cho,et al. A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancer , 2014, Cancer Chemotherapy and Pharmacology.
[146] J. O’Shaughnessy. Pegylated liposomal doxorubicin in the treatment of breast cancer. , 2003, Clinical breast cancer.
[147] P. Couvreur,et al. Nanoparticles in cancer therapy and diagnosis. , 2002, Advanced drug delivery reviews.
[148] M. Dewhirst,et al. Thermosensitive liposomes: extravasation and release of contents in tumor microvascular networks. , 1996, International journal of radiation oncology, biology, physics.
[149] David S. Horne,et al. Casein micelle structure : Models and muddles , 2006 .
[150] F. Rinaldi,et al. Niosomes from 80s to present: the state of the art. , 2014, Advances in colloid and interface science.
[151] M. Muhammed,et al. Biodegradable polymeric vesicles containing magnetic nanoparticles, quantum dots and anticancer drugs for drug delivery and imaging. , 2014, Biomaterials.
[152] M. Singh,et al. Novel colloidal carriers for psoriasis: current issues, mechanistic insight and novel delivery approaches. , 2013, Journal of controlled release : official journal of the Controlled Release Society.
[153] Hong Wu,et al. Improved therapeutic effect of DOX-PLGA-PEG micelles decorated with bivalent fragment HAb18 F(ab')(2) for hepatocellular carcinoma. , 2010, Biomacromolecules.
[154] Robert Gurny,et al. Drug-loaded nanoparticles : preparation methods and drug targeting issues , 1993 .
[155] Youqing Shen,et al. Fabrication of micellar nanoparticles for drug delivery through the self-assembly of block copolymers , 2010 .
[156] Kai Yang,et al. Nano-graphene in biomedicine: theranostic applications. , 2013, Chemical Society reviews.
[157] D. Tomalia. Birth of a new macromolecular architecture: dendrimers as quantized building blocks for nanoscale synthetic polymer chemistry , 2005 .
[158] R Blumenthal,et al. Design of liposomes for enhanced local release of drugs by hyperthermia. , 1978, Science.
[159] Y. Nakanishi,et al. Antitumor effect of MCC‐465, pegylated liposomal doxorubicin tagged with newly developed monoclonal antibody GAH, in colorectal cancer xenografts , 2004, Cancer science.
[160] Kinam Park. Albumin: a versatile carrier for drug delivery. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[161] María J. Vicent,et al. Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. , 2009, Advanced drug delivery reviews.
[162] J. Schnitzer. gp60 is an albumin-binding glycoprotein expressed by continuous endothelium involved in albumin transcytosis. , 1992, The American journal of physiology.
[163] K. Beningo,et al. Fc-receptor-mediated phagocytosis is regulated by mechanical properties of the target. , 2002, Journal of cell science.
[164] Felix Kratz,et al. Impact of albumin on drug delivery--new applications on the horizon. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[165] A. Schätzlein,et al. Dendrimers in gene delivery. , 2005, Advanced drug delivery reviews.
[166] H. Hansen,et al. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. , 1972, Cancer chemotherapy reports.
[167] S. Mitragotri,et al. Adaptive micro and nanoparticles: temporal control over carrier properties to facilitate drug delivery. , 2011, Advanced drug delivery reviews.
[168] R. Schubert,et al. Effect of beta-sitosterol on the characteristics of vesicular gels containing chlorhexidine. , 2004, International journal of pharmaceutics.
[169] Thomas L Andresen,et al. Liposome imaging agents in personalized medicine. , 2012, Advanced drug delivery reviews.
[170] N. Desai. Nanoparticle albumin bound (nab) technology: targeting tumors through the endothelial gp60 receptor and SPARC , 2007 .
[171] J. Fréchet,et al. Dendrimers and dendritic polymers in drug delivery. , 2005, Drug discovery today.
[172] B. Kinsey,et al. Targeted delivery of expression plasmids to the lung via macroaggregated polyethylenimine-albumin conjugates. , 2003, Methods in molecular medicine.
[173] You Han Bae,et al. Drug targeting and tumor heterogeneity. , 2009, Journal of controlled release : official journal of the Controlled Release Society.
[174] George R. Newkome,et al. MICELLES. PART 1. CASCADE MOLECULES: A NEW APPROACH TO MICELLES. A (27)-ARBOROL , 1985 .
[175] G. P. Kumar,et al. Nonionic surfactant vesicular systems for effective drug delivery—an overview , 2011 .
[176] Y. Barenholz. Doxil®--the first FDA-approved nano-drug: lessons learned. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[177] I. Uchegbu,et al. Non-ionic surfactant vesicles (niosomes): Physical and pharmaceutical chemistry , 1995 .
[178] Y. M. Lee,et al. Taxol-loaded block copolymer nanospheres composed of methoxy poly(ethylene glycol) and poly(epsilon-caprolactone) as novel anticancer drug carriers. , 2001, Biomaterials.
[179] G M Tozer,et al. Modification of tumor blood flow: current status and future directions. , 1998, Seminars in radiation oncology.
[180] Tianwei Tan,et al. Studies on the oridonin-loaded poly(D,L-lactic acid) nanoparticles in vitro and in vivo. , 2007, International journal of biological macromolecules.
[181] K. Ulbrich,et al. Treatment with HPMA copolymer-based doxorubicin conjugate containing human immunoglobulin induces long-lasting systemic anti-tumour immunity in mice , 2006, Cancer Immunology, Immunotherapy.
[182] M. Michaelis,et al. Preparation, characterisation and maintenance of drug efficacy of doxorubicin-loaded human serum albumin (HSA) nanoparticles. , 2007, International journal of pharmaceutics.
[183] Jacques Ferlay,et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 [Internet] , 2013 .
[184] J. Kopeček,et al. Combination cytotoxicity of backbone degradable HPMA copolymer gemcitabine and platinum conjugates toward human ovarian carcinoma cells. , 2014, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[185] Adrian C. Williams,et al. Skin delivery of 5‐fluorouracil from ultradeformable and standard liposomes in‐vitro , 2001, The Journal of pharmacy and pharmacology.
[186] Adrian C. Williams,et al. Skin Delivery of Oestradiol from Deformable and Traditiona Liposomes: Mechanistic Studies , 1999, The Journal of pharmacy and pharmacology.
[187] M. Otagiri,et al. Pharmaceutical Strategies Utilizing Recombinant Human Serum Albumin , 2002, Pharmaceutical Research.
[188] A. Gabizon. Stealth liposomes and tumor targeting: one step further in the quest for the magic bullet. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[189] A. Tolcher,et al. A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[190] B. Leyland-Jones,et al. Hypersensitivity reactions from taxol. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[191] Y. Barenholz,et al. Physical (in) stability of liposomes upon chemical hydrolysis: the role of lysophospholipids and fatty acids. , 1995, Biochimica et biophysica acta.
[192] F. Chang,et al. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial? , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[193] Y. Assaraf,et al. Beta-casein-based nanovehicles for oral delivery of chemotherapeutic drugs: drug-protein interactions and mitoxantrone loading capacity. , 2010, Nanomedicine : nanotechnology, biology, and medicine.
[194] H. Maeda,et al. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.
[195] A. R. Kulkarni,et al. Biodegradable polymeric nanoparticles as drug delivery devices. , 2001, Journal of controlled release : official journal of the Controlled Release Society.
[196] M. Uesaka,et al. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. , 2011, Nature nanotechnology.
[197] Z. Yi,et al. Poly(gamma,L-glutamic acid)-cisplatin conjugate effectively inhibits human breast tumor xenografted in nude mice. , 2006, Biomaterials.
[198] C. Mathers,et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer , 2013 .
[199] W. Gradishar,et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[200] J. Verweij,et al. Phase I Pharmacokinetic, Food Effect, and Pharmacogenetic Study of Oral Irinotecan Given as Semisolid Matrix Capsules in Patients with Solid Tumors , 2005, Clinical Cancer Research.
[201] P. Low,et al. Folate-targeted therapeutic and imaging agents for cancer. , 2009, Current opinion in chemical biology.
[202] Vladimir P Torchilin,et al. Lipid-core micelles for targeted drug delivery. , 2005, Current drug delivery.
[203] R. Tekade,et al. Ethosomes and ultradeformable liposomes for transdermal delivery of clotrimazole: A comparative assessment. , 2012, Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society.
[204] T. Saba. Physiology and physiopathology of the reticuloendothelial system. , 1970, Archives of internal medicine.
[205] R. Andreesen,et al. Disturbance of phospholipid metabolism during the selective destruction of tumor cells induced by alkyl-lysophospholipids. , 1979, Cancer research.
[206] G. Cevc. Transfersomes, liposomes and other lipid suspensions on the skin: permeation enhancement, vesicle penetration, and transdermal drug delivery. , 1996, Critical reviews in therapeutic drug carrier systems.
[207] M. Amiji,et al. Poly(ethylene oxide)-modified poly(ɛ-caprolactone) nanoparticles for targeted delivery of tamoxifen in breast cancer , 2005 .
[208] J. Pardeike,et al. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. , 2009, International journal of pharmaceutics.
[209] J. Brender,et al. Solid-state NMR reveals the hydrophobic-core location of poly(amidoamine) dendrimers in biomembranes. , 2010, Journal of the American Chemical Society.
[210] J. Bouwstra,et al. Vesicles as a tool for transdermal and dermal delivery. , 2005, Drug discovery today. Technologies.
[211] Karsten Mäder,et al. Investigations on the structure of solid lipid nanoparticles (SLN) and oil-loaded solid lipid nanoparticles by photon correlation spectroscopy, field-flow fractionation and transmission electron microscopy. , 2004, Journal of controlled release : official journal of the Controlled Release Society.
[212] G. Salzano,et al. Polymeric micelles containing reversibly phospholipid-modified anti-survivin siRNA: a promising strategy to overcome drug resistance in cancer. , 2014, Cancer letters.
[213] A. Malik,et al. Gp60 Activation Mediates Albumin Transcytosis in Endothelial Cells by Tyrosine Kinase-dependent Pathway* , 1997, The Journal of Biological Chemistry.
[214] Y. Shechter,et al. Albumin-insulin conjugate releasing insulin slowly under physiological conditions: a new concept for long-acting insulin. , 2005, Bioconjugate chemistry.
[215] Y. D. Livney,et al. Milk proteins as vehicles for bioactives , 2010 .
[216] Alexander V Kabanov,et al. Nanocarriers for delivery of platinum anticancer drugs. , 2013, Advanced drug delivery reviews.
[217] M. R. Mozafari,et al. Liposomes: an overview of manufacturing techniques. , 2005, Cellular & molecular biology letters.
[218] A. Malik,et al. Size and dynamics of caveolae studied using nanoparticles in living endothelial cells. , 2009, ACS nano.
[219] Shashank K Singh,et al. Synthesis, characterization and mechanistic-insight into the anti-proliferative potential of PLGA-gemcitabine conjugate. , 2014, International journal of pharmaceutics.
[220] Y. Assaraf,et al. Beta-casein Nanoparticles as an Oral Delivery System for Chemotherapeutic Drugs: Impact of Drug Structure and Properties on Co-assembly , 2010, Pharmaceutical Research.
[221] E. Gamelin,et al. Relationship between 5‐fluorouracil (5‐FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5‐FU , 1996, Cancer.
[222] Véronique Préat,et al. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. , 2010, Journal of controlled release : official journal of the Controlled Release Society.
[223] V. Torchilin,et al. Multifunctionality of lipid-core micelles for drug delivery and tumour targeting , 2010, Molecular membrane biology.
[224] S. Svenson. What nanomedicine in the clinic right now really forms nanoparticles? , 2014, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.
[225] Sonke Svenson,et al. Dendrimers as versatile platform in drug delivery applications. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[226] G. Cevc,et al. Lipid vesicles penetrate into intact skin owing to the transdermal osmotic gradients and hydration force. , 1992, Biochimica et biophysica acta.
[227] G. E. El Maghraby,et al. Oestradiol skin delivery from ultradeformable liposomes: refinement of surfactant concentration. , 2000, International journal of pharmaceutics.
[228] F. Yuan,et al. Transvascular drug delivery in solid tumors. , 1998, Seminars in radiation oncology.
[229] M. Blanco-Prieto,et al. Lipid nanoparticles protect from edelfosine toxicity in vivo. , 2014, International journal of pharmaceutics.
[230] Kazunori Kataoka,et al. Intelligent polymeric micelles from functional poly(ethylene glycol)-poly(amino acid) block copolymers. , 2009, Advanced drug delivery reviews.
[231] R. Duncan,et al. Dendrimer-platinate: a novel approach to cancer chemotherapy. , 1999, Anti-cancer drugs.
[232] George R. Newkome,et al. Micelles. Part 1. Cascade molecules: a new approach to micelles. A [27]-arborol , 1985 .
[233] Yang Yang,et al. Oridonin, a diterpenoid purified from Rabdosia rubescens, inhibits the proliferation of cells from lymphoid malignancies in association with blockade of the NF-κB signal pathways , 2005, Molecular Cancer Therapeutics.
[234] V. Torchilin. Recent advances with liposomes as pharmaceutical carriers , 2005, Nature Reviews Drug Discovery.